Emerging new anticancer therapies in 2013.
OBJECTIVE
Year 2013 has been rich in presentations and publications about new emerging anticancer agents, both in peer-review journals and in international meetings such as American Society of Clinical Oncology (ASCO), European Cancer Congress (European Cancer Organization - ECCO/European Society of Medical Oncology - ESMO), American Association for Cancer Research Meeting (AACR), Molecular Target and Cancer Therapeutics AACR-NCI-EORTC International Conference and Targeted Anticancer Therapies Meeting (TAT). Our purpose is to give an update in 2013's most important advances in new anticancer therapies.


RESULTS
We will highlight recent advances in immunotherapy; combinations of targeted agents to overcome resistance; second and third generation of targeted agents against oncogene addiction and new antibody-drug conjugates against epithelial tumors.


CONCLUSIONS
Future implications of this year's emerging therapies will probably lead to the approval of new immunotherapies for treatment of several tumor types and second-generation agents to overcome resistance in those tumors with oncogene addiction.
Departement of Medical Oncology, Institut Claudius Regaud, Toulouse, France.
Carlos
C
Gomez-Roca
Jean-Pierre
JP
Delord
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D058990:Molecular Targeted Therapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D047428:Protein Kinase Inhibitors